Berkeley Heights, NJ — Genta Incorporated announced today the appointments of Ana I. Stancic and Marvin E. Jaffe, MD, as members of the company’s Board of Directors. The Company also announced the retirement from the board of Mr. Douglas G. Watson.

Raymond P. Warrell, Jr, Genta’s chairman and CEO commented: "The Genta team is delighted to welcome our new independent directors. Ms. Stancic’s breadth of experience in finance, accounting, compliance, and business development should greatly enhance the board’s financial guidance. Dr. Jaffe’s long track record of successful drug development should provide pivotal insights into a year wherein we complete a pivotal Genasense program and initiate the new Phase III program with tesetaxel."

"The Board extends our deepest gratitude to Doug Watson, who has served on the Genta board for the past 8 years. During his tenure, Doug’s counsel, judgment, wisdom and guidance to his colleagues have been invaluable, and we wish him continued success with his myriad endeavors."

Stancic brings extensive and diversified finance and accounting experience from a long career in healthcare and biotechnology. She is
currently senior vice president and CFO at M2Gen, a wholly owned, for-profit subsidiary of the Moffitt Cancer Center, where
she provides direction, leadership, and management for all financial operations, controls, internal audits, and facility administration. Previously, she was CFO of Aureon Bioscience Inc, an oncology diagnostic company. From 2007 to 2008, she was executive
vice president and CFO at OMRIX Biopharmaceuticals Inc,  which was acquired by Johnson and Johnson.

Jaffe has spent his career in the pharmaceutical industry and has been responsible for the pre-clinical and clinical development of new drugs and biologics in nearly every therapeutic area. He worked for 18 years at Merck & Co., eventually rising to the position of
senior vice president of Medical Affairs. After leaving Merck, Jaffe became the founding president of the RW Johnson Pharmaceutical
Research Institute (PRI), a Johnson & Johnson Company. PRI was established for the purpose of providing globally integrated research
and development support to several companies within the J&J pharmaceutical sector. Jaffe retired from Johnson & Johnson in 1994
and currently serves as a consultant and board member to the biopharmaceutical and biotechnology industries.

SOURCE: Genta Incorporated